KR20200017495A - Nk-92 세포 및 il-15 효능제의 조합 요법 - Google Patents

Nk-92 세포 및 il-15 효능제의 조합 요법 Download PDF

Info

Publication number
KR20200017495A
KR20200017495A KR1020207001267A KR20207001267A KR20200017495A KR 20200017495 A KR20200017495 A KR 20200017495A KR 1020207001267 A KR1020207001267 A KR 1020207001267A KR 20207001267 A KR20207001267 A KR 20207001267A KR 20200017495 A KR20200017495 A KR 20200017495A
Authority
KR
South Korea
Prior art keywords
cells
administered
subject
cancer
merkel cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207001267A
Other languages
English (en)
Korean (ko)
Inventor
한스 클링게만
티엔 리
로렌스 보이셀
Original Assignee
난트케이웨스트, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 난트케이웨스트, 인크. filed Critical 난트케이웨스트, 인크.
Publication of KR20200017495A publication Critical patent/KR20200017495A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207001267A 2017-06-20 2018-06-19 Nk-92 세포 및 il-15 효능제의 조합 요법 Ceased KR20200017495A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522319P 2017-06-20 2017-06-20
US62/522,319 2017-06-20
PCT/US2018/038312 WO2018236890A1 (en) 2017-06-20 2018-06-19 Nk-92 cells and il-15 agonist combination therapy

Publications (1)

Publication Number Publication Date
KR20200017495A true KR20200017495A (ko) 2020-02-18

Family

ID=62875319

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207001267A Ceased KR20200017495A (ko) 2017-06-20 2018-06-19 Nk-92 세포 및 il-15 효능제의 조합 요법

Country Status (9)

Country Link
US (1) US20200121720A1 (https=)
EP (1) EP3641799A1 (https=)
JP (1) JP2020524167A (https=)
KR (1) KR20200017495A (https=)
CN (1) CN110740747A (https=)
AU (1) AU2018288715A1 (https=)
CA (1) CA3066465A1 (https=)
IL (1) IL270840A (https=)
WO (1) WO2018236890A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7267398A (en) 1997-04-30 1998-11-24 Hans Klingemann Natural killer cell lines and methods of use
EP1718670B1 (en) 2004-02-27 2011-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Also Published As

Publication number Publication date
WO2018236890A1 (en) 2018-12-27
AU2018288715A1 (en) 2019-12-12
US20200121720A1 (en) 2020-04-23
CA3066465A1 (en) 2018-12-27
IL270840A (en) 2020-01-30
JP2020524167A (ja) 2020-08-13
EP3641799A1 (en) 2020-04-29
CN110740747A (zh) 2020-01-31

Similar Documents

Publication Publication Date Title
Najafi et al. The current knowledge concerning solid cancer and therapy
KR101512503B1 (ko) 개선된 항종양 치료
Siu et al. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
US20150344577A1 (en) Agents for treating tumors, use and method thereof
CN105828834A (zh) 检查点抑制剂和治疗剂的组合以治疗癌症
JP2015505313A (ja) 癌を治療するための併用療法
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
JP2011506467A (ja) 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
KR20200017494A (ko) Nk-92 세포를 사용하여 메르켈 세포 암종 (mcc)을 치료하는 방법
CN115362253B (zh) 利用维奈托克增强t细胞的方法
KR20200017495A (ko) Nk-92 세포 및 il-15 효능제의 조합 요법
JP2022512927A (ja) 癌を処置するための組成物および方法
HK40021263A (en) Nk-92 cells and il-15 agonist combination therapy
JP2014221752A (ja) ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬
HK40022820A (en) Methods for treating merkel cell carcinoma (mcc) using nk-92 cells
KR102558989B1 (ko) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
KR101988124B1 (ko) 암 연관 섬유아세포 표적용 약학적 조성물
HALL et al. Combination of cannabidiol with low-dose naltrexone increases the anticancer action of chemotherapyin vitroandin vivo
Liu Hypoxia Activated Prodrug and Anti-Angiogenic Therapy Cooperate to Treat Pancreatic Cancer But Elicit Immune Suppressive G-Mdsc Infiltration
Kuang solid tumors: A new concept in
Husieva et al. Drug classification for the treatment of hematologic malignancies
US20210186978A1 (en) Combination therapy
EP4188524A1 (en) Combination therapy for treatment of cancer
KR20200124661A (ko) 종양 성장을 감소시키기 위한 미나프린의 용도
Di Biase Differential Stress Resistance (DSR) and Differential Stress Sensitization (DSS); Molecular Mechanisms Behind the Efficacy of Short-Term Starvation (STS)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230308

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230711

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230308

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I